Regulation of soluble guanylate cyclase by matricellular thrombospondins: Implications for blood flow

Frontiers in Physiology

Volumn 5 APR, Issue , 2014, Pages

  Rogers, Natasha M ^a   Seeger, Franziska ^b   Garcin, Elsa D ^b   Roberts, David D ^c   Isenberg, Jeffrey S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cardiovascular disease; CD47; Cyclic guanosine monophosphate; Nitric oxide; ROS; Soluble guanylate cyclase; Thrombospondin 1

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; AMYLOID BETA PROTEIN; ANTISENSE OLIGONUCLEOTIDE; ATACIGUAT; BAY 60 2770; CD36 ANTIGEN; CD47 ANTIGEN; CINACIGUAT; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; LIFICIGUAT; MESOPORPHYRIN; NITRITE; REACTIVE OXYGEN METABOLITE; RIOCIGUAT; THROMBOSPONDIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ANGIOGENESIS; BLOOD FLOW; CARDIOVASCULAR DISEASE; CELL SURVIVAL; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HYPOTENSION; IC 50; ISCHEMIA; KIDNEY ISCHEMIA; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; TISSUE PERFUSION;

EID: 84901059997     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00134     Document Type: Review

References (206)

1. Adams, J. C., and Lawler, J. (2011). The thrombospondins. Cold Spring Harb. Perspect. Biol. 3:a009712. doi: 10.1101/cshperspect.a009712
2. Agullo, L., Garcia-Dorado, D., Escalona, N., Ruiz-Meana, M., Mirabet, M., Inserte, J., et al. (2005). Membrane association of nitric oxide-sensitive guanylyl cyclase in cardiomyocytes. Cardiovasc. Res. 68, 65-74. doi: 10.1016/j.cardiores.2005.05.021
3. Allerston, C. K., von Delft, F., and Gileadi, O. (2013). Crystal structures of the catalytic domain of human soluble guanylate cyclase. PLoS ONE 8:e57644. doi: 10.1371/journal.pone.0057644
4. Arnold, W. P., Mittal, C. K., Katsuki, S., and Murad, F. (1977). Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. U.S.A. 74, 3203-3207. doi: 10.1073/pnas.74.8.3203
5. Baenziger, N. L., Brodie, G. N., and Majerus, P. W. (1971). A thrombin-sensitive protein of human platelet membranes. Proc. Natl. Acad. Sci. U.S.A. 68, 240-243. doi: 10.1073/pnas.68.1.240
6. Bagavandoss, P., Kaytes, P., Vogeli, G., Wells, P. A., and Wilks, J. W. (1993). Recombinant truncated thrombospondin-1 monomer modulates endothelial cell plasminogen activator inhibitor 1 accumulation and proliferation in vitro. Biochem. Biophys. Res. Commun. 192, 325-332. doi: 10.1006/bbrc.1993.1418
7. Balashova, N., Chang, F. J., Lamothe, M., Sun, Q., and Beuve, A. (2005). Characterization of a novel type of endogenous activator of soluble guanylyl cyclase. J. Biol. Chem. 280, 2186-2196. doi: 10.1074/jbc.M411545200
8. Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., and Landreth, G. E. (2003). A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J. Neurosci. 23, 2665-2674.
9. Baskaran, P., Heckler, E. J., van den Akker, F., and Beuve, A. (2011). Identification of residues in the heme domain of soluble guanylyl cyclase that are important for basal and stimulated catalytic activity. PLoS ONE 6:e26976. doi: 10.1371/journal.pone.0026976
10. Bauer, E. M., Qin, Y., Miller, T. W., Bandle, R. W., Csanyi, G., Pagano, P. J., et al. (2010). Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc. Res. 88, 471-481. doi: 10.1093/cvr/cvq218
11. Bauer, P. M., Bauer, E. M., Rogers, N. M., Yao, M., Feijoo-Cuaresma, M., Pilewski, J. M., et al. (2012). Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc. Res. 93, 682-693. doi: 10.1093/cvr/cvr356
12. Bauersachs, J., Bouloumie, A., Mulsch, A., Wiemer, G., Fleming, I., and Busse, R. (1998). Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Cardiovasc. Res. 37, 772-779. doi: 10.1016/S0008-6363(97)00250-2
13. Bellamy, T. C., Wood, J., Goodwin, D. A., and Garthwaite, J. (2000). Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses. Proc. Natl. Acad. Sci. U.S.A. 97, 2928-2933. doi: 10.1073/pnas.97.6.2928
14. Bonnefoy, A., Daenens, K., Feys, H. B., De Vos, R., Vandervoort, P., Vermylen, J., et al. (2006). Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood 107, 955-964. doi: 10.1182/blood-2004-12-4856
15. Bornstein, P. (2009). Matricellular proteins: an overview. J. Cell Commun. Signal. 3, 163-165. doi: 10.1007/s12079-009-0069-z
16. Bornstein, P., Devarayalu, S., Li, P., Disteche, C. M., and Framson, P. (1991). A second thrombospondin gene in the mouse is similar in organization to thrombospondin 1 but does not respond to serum. Proc. Natl. Acad. Sci. U.S.A. 88, 8636-8640. doi: 10.1073/pnas.88.19.8636
17. Brandish, P. E., Buechler, W., and Marletta, M. A. (1998). Regeneration of the ferrous heme of soluble guanylate cyclase from the nitric oxide complex: acceleration by thiols and oxyhemoglobin. Biochemistry 37, 16898-16907. doi: 10.1021/bi9814989
18. Brandwein, H. J., Lewicki, J. A., and Murad, F. (1981). Reversible inactivation of guanylate cyclase by mixed disulfide formation. J. Biol. Chem. 256, 2958-2962.
19. Brandwein, H. J., Lewicki, J. A., Waldman, S. A., and Murad, F. (1982). Effect of GTP analogues on purified soluble guanylate cyclase. J. Biol. Chem. 257, 1309-1311.
20. Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. R., et al. (1996). Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell 84, 757-767. doi: 10.1016/S0092-8674(00)81053-3
21. Brown, E. J., and Frazier, W. A. (2001). Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11, 130-135. doi: 10.1016/S0962-8924(00)01906-1
22. Buechler, W. A., Nakane, M., and Murad, F. (1991). Expression of soluble guanylate cyclase activity requires both enzyme subunits. Biochem. Biophys. Res. Commun. 174, 351-357. doi: 10.1016/0006-291X(91)90527-E
23. Busker, M., Neidhardt, I., and Behrends, S. (2014). Nitric oxide activation of guanylate cyclase pushes the alpha1 signaling helix and the beta1 heme-binding domain closer to the substrate-binding site. J. Biol. Chem. 289, 476-484. doi: 10.1074/jbc.M113.504472
24. Cai, H., and Harrison, D. G. (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87, 840-844. doi: 10.1161/01.RES.87.10.840
25. Calzada, M. J., Sipes, J. M., Krutzsch, H. C., Yurchenco, P. D., Annis, D. S., Mosher, D. F., et al. (2003). Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha6beta1 integrin. J. Biol. Chem. 278, 40679-40687. doi: 10.1074/jbc.M302014200
26. Campbell, M. G., Underbakke, E. S., Potter, C. S., Carragher, B., and Marletta, M. A. (2014). Single-particle EM reveals the higher-order domain architecture of soluble guanylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 111, 2960-2965. doi: 10.1073/pnas.1400711111
27. Cannon, J. E., and Pepke-Zaba, J. (2014). Riociguat for pulmonary hypertension. Expert Rev. Clin. Pharmacol. doi: 10.1586/17512433.2014.893818. [Epub ahead of print].
28. Cary, S. P., Winger, J. A., and Marletta, M. A. (2005). Tonic and acute nitric oxide signaling through soluble guanylate cyclase is mediated by nonheme nitric oxide, ATP, and GTP. Proc. Natl. Acad. Sci. U.S.A. 102, 13064-13069. doi: 10.1073/pnas.0506289102
29. Chang, F. J., Lemme, S., Sun, Q., Sunahara, R. K., and Beuve, A. (2005). Nitric oxide-dependent allosteric inhibitory role of a second nucleotide binding site in soluble guanylyl cyclase. J. Biol. Chem. 280, 11513-11519. doi: 10.1074/jbc.M412203200
30. Chen, K., and Keaney, J. F. Jr. (2012). Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease. Curr. Atheroscler. Rep. 14, 476-483. doi: 10.1007/s11883-012-0266-8
31. Chester, M., Seedorf, G., Tourneux, P., Gien, J., Tseng, N., Grover, T., et al. (2011). Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 301, L755-764. doi: 10.1152/ajplung.00138.2010
32. Choi, H., Tostes, R. C., and Webb, R. C. (2011). Thioredoxin reductase inhibition reduces relaxation by increasing oxidative stress and s-nitrosylation in mouse aorta. J. Cardiovasc. Pharmacol. 58, 522-527. doi: 10.1097/FJC.0b013e31822d80a5
33. Cifuentes, M. E., and Pagano, P. J. (2006). Targeting reactive oxygen species in hypertension. Curr. Opin. Nephrol. Hypertens. 15, 179-186. doi: 10.1097/01.mnh.0000214776.19233.68
34. Csanyi, G., Yao, M., Rodriguez, A. I., Al Ghouleh, I., Sharifi-Sanjani, M., Frazziano, G., et al. (2012). Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler. Thromb. Vasc. Biol. 32, 2966-2973. doi: 10.1161/ATVBAHA.112.300031
35. Dawson, D. W., Pearce, S. F., Zhong, R., Silverstein, R. L., Frazier, W. A., and Bouck, N. P. (1997). CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707-717. doi: 10.1083/jcb.138.3.707
36. Derbyshire, E. R., Gunn, A., Ibrahim, M., Spiro, T. G., Britt, R. D., and Marletta, M. A. (2008). Characterization of two different five-coordinate soluble guanylate cyclase ferrous-nitrosyl complexes. Biochemistry 47, 3892-3899. doi: 10.1021/bi7022943
37. Derbyshire, E. R., and Marletta, M. A. (2012). Structure and regulation of soluble guanylate cyclase. Annu. Rev. Biochem. 81, 533-559. doi: 10.1146/annurev-biochem-050410-100030
38. Dierks, E., Hu, S., Vogel, K., Yu, A., and Spiro, T. J. B. (1997). Demonstration of the role of scission of the proximal histidine-iron bond in the activation of soluble guanylyl cyclase through metalloporphyrin substitution studies. J. Am. Chem. Soc. 119, 7316-7323. doi: 10.1021/ja9603057
39. Erbil, W. K., Price, M. S., Wemmer, D. E., and Marletta, M. A. (2009). A structural basis for H-NOX signaling in Shewanella oneidensis by trapping a histidine kinase inhibitory conformation. Proc. Natl. Acad. Sci. U.S.A. 106, 19753-19760. doi: 10.1073/pnas.0911645106
40. Erdmann, E., Semigran, M. J., Nieminen, M. S., Gheorghiade, M., Agrawal, R., Mitrovic, V., et al. (2013). Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur. Heart J. 34, 57-67. doi: 10.1093/eurheartj/ehs196
41. Evgenov, O. V., Pacher, P., Schmidt, P. M., Haskó, G., and Stasch, J. P. (2006). NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 5, 755-768. doi: 10.1038/nrd2038
42. Favier, J., Germain, S., Emmerich, J., Corvol, P., and Gasc, J. M. (2005). Critical overexpression of thrombospondin 1 in chronic leg ischaemia. J. Pathol. 207, 358-366. doi: 10.1002/path.1833
43. Fernhoff, N. B., Derbyshire, E. R., and Marletta, M. A. (2009). A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 106, 21602-21607. doi: 10.1073/pnas.0911083106
44. Ferrero, R., Rodriguez-Pascual, F., Miras-Portugal, M. T., and Torres, M. (2000). Nitric oxide-sensitive guanylyl cyclase activity inhibition through cyclic GMP-dependent dephosphorylation. J. Neurochem. 75, 2029-2039. doi: 10.1046/j.1471-4159.2000.0752029.x
45. Fritz, B. G., Hu, X., Brailey, J. L., Berry, R. E., Walker, F. A., and Montfort, W. R. (2011). Oxidation and loss of heme in soluble guanylyl cyclase from Manduca sexta. Biochemistry 50, 5813-5815. doi: 10.1021/bi200794c
46. Fritz, B. G., Roberts, S. A., Ahmed, A., Breci, L., Li, W., Weichsel, A., et al. (2013). Molecular model of a soluble guanylyl cyclase fragment determined by small-angle X-ray scattering and chemical cross-linking. Biochemistry 52, 1568-1582. doi: 10.1021/bi301570m
47. Gao, S., Hsieh, C. L., Bhansali, M., Kannan, A., and Shemshedini, L. (2013). A peptide against soluble guanylyl cyclase alpha1: a new approach to treating prostate cancer. PLoS ONE 8:e64189. doi: 10.1371/journal.pone.0064189
48. Garthwaite, J., Southam, E., Boulton, C. L., Nielsen, E. B., Schmidt, K., and Mayer, B. (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 48, 184-188.
49. Gerassimou, C., Kotanidou, A., Zhou, Z., Simoes, D. C., Roussos, C., and Papapetropoulos, A. (2007). Regulation of the expression of soluble guanylyl cyclase by reactive oxygen species. Br. J. Pharmacol. 150, 1084-1091. doi: 10.1038/sj.bjp.0707179
50. Gerzer, R., Hofmann, F., and Schultz, G. (1981). Purification of a soluble, sodium-nitroprusside-stimulated guanylate cyclase from bovine lung. Eur. J. Biochem. 116, 479-486. doi: 10.1111/j.1432-1033.1981.tb05361.x
51. Ghofrani, H. A., Galie, N., Grimminger, F., Grunig, E., Humbert, M., Jing, Z. C., et al. (2013). Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369, 330-340. doi: 10.1056/NEJMoa1209655
52. Ghosh, A., and Stuehr, D. J. (2012). Soluble guanylyl cyclase requires heat shock protein 90 for heme insertion during maturation of the NO-active enzyme. Proc. Natl. Acad. Sci. U.S.A. 109, 12998-13003. doi: 10.1073/pnas.1205854109
53. Gille, A., Lushington, G. H., Mou, T. C., Doughty, M. B., Johnson, R. A., and Seifert, R. (2004). Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J. Biol. Chem. 279, 19955-19969. doi: 10.1074/jbc.M312560200
54. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., et al. (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U.S.A. 87, 6624-6628. doi: 10.1073/pnas.87.17.6624
55. Goodrich, L. E., Paulat, F., Praneeth, V. K., and Lehnert, N. (2010). Electronic structure of heme-nitrosyls and its significance for nitric oxide reactivity, sensing, transport, and toxicity in biological systems. Inorg. Chem. 49, 6293-6316. doi: 10.1021/ic902304a
56. Gruetter, C. A., Kadowitz, P. J., and Ignarro, L. J. (1981). Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Can. J. Physiol. Pharmacol. 59, 150-156. doi: 10.1139/y81-025
57. Guo, N., Krutzsch, H. C., Inman, J. K., and Roberts, D. D. (1997). Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 57, 1735-1742.
58. Gupta, G., Azam, M., Yang, L., and Danziger, R. S. (1997). The beta2 subunit inhibits stimulation of the alpha1/beta1 form of soluble guanylyl cyclase by nitric oxide. Potential relevance to regulation of blood pressure. J. Clin. Invest. 100, 1488-1492. doi: 10.1172/JCI119670
59. Haase, T., Haase, N., Kraehling, J. R., and Behrends, S. (2010). Fluorescent fusion proteins of soluble guanylyl cyclase indicate proximity of the heme nitric oxide domain and catalytic domain. PLoS ONE 5:e11617. doi: 10.1371/journal.pone.0011617
60. Heckler, E. J., Crassous, P. A., Baskaran, P., and Beuve, A. (2013). Protein disulfide-isomerase interacts with soluble guanylyl cyclase via a redox-based mechanism and modulates its activity. Biochem. J. 452, 161-169. doi: 10.1042/BJ20130298
61. Iruela-Arispe, M. L., Lombardo, M., Krutzsch, H. C., Lawler, J., and Roberts, D. D. (1999). Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100, 1423-1431. doi: 10.1161/01.CIR.100.13.1423
62. Isenberg, J. S., Annis, D. S., Pendrak, M. L., Ptaszynska, M., Frazier, W. A., Mosher, D. F., et al. (2009a). Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J. Biol. Chem. 284, 1116-1125. doi: 10.1074/jbc.M804860200
63. Isenberg, J. S., Frazier, W. A., Krishna, M. C., Wink, D. A., and Roberts, D. D. (2008a). Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling. Curr. Drug Targets 9, 833-841. doi: 10.2174/138945008785909338
64. Isenberg, J. S., Hyodo, F., Matsumoto, K., Romeo, M. J., Abu-Asab, M., Tsokos, M., et al. (2007a). Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 109, 1945-1952. doi: 10.1182/blood-2006-08-041368
65. Isenberg, J. S., Hyodo, F., Pappan, L. K., Abu-Asab, M., Tsokos, M., Krishna, M. C., et al. (2007b). Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler. Thromb. Vasc. Biol. 27, 2582-2588. doi: 10.1161/ATVBAHA.107.155390
66. Isenberg, J. S., Jia, Y., Fukuyama, J., Switzer, C. H., Wink, D. A., and Roberts, D. D. (2007c). Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J. Biol. Chem. 282, 15404-15415. doi: 10.1074/jbc.M701638200
67. Isenberg, J. S., Martin-Manso, G., Maxhimer, J. B., and Roberts, D. D. (2009b). Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat. Rev. Cancer 9, 182-194. doi: 10.1038/nrc2561
68. Isenberg, J. S., Maxhimer, J. B., Powers, P., Tsokos, M., Frazier, W. A., and Roberts, D. D. (2008b). Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery 144, 752-761. doi: 10.1016/j.surg.2008.07.009
69. Isenberg, J. S., Pappan, L. K., Romeo, M. J., Abu-Asab, M., Tsokos, M., Wink, D. A., et al. (2008c). Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann. Surg. 247, 180-190. doi: 10.1097/SLA.0b013e31815685dc
70. Isenberg, J. S., Qin, Y., Maxhimer, J. B., Sipes, J. M., Despres, D., Schnermann, J., et al. (2009c). Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol. 28, 110-119. doi: 10.1016/j.matbio.2009.01.002
71. Isenberg, J. S., Ridnour, L. A., Dimitry, J., Frazier, W. A., Wink, D. A., and Roberts, D. D. (2006a). CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J. Biol. Chem. 281, 26069-26080. doi: 10.1074/jbc.M605040200
72. Isenberg, J. S., Ridnour, L. A., Espey, M. G., Wink, D. A., and Roberts, D. D. (2005a). Nitric oxide in wound-healing. Microsurgery 25, 442-451. doi: 10.1002/micr.20168
73. Isenberg, J. S., Ridnour, L. A., Perruccio, E. M., Espey, M. G., Wink, D. A., and Roberts, D. D. (2005b). Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 102, 13141-13146. doi: 10.1073/pnas.0502977102
74. Isenberg, J. S., Romeo, M. J., Abu-Asab, M., Tsokos, M., Oldenborg, A., Pappan, L., et al. (2007d). Increasing survival of ischemic tissue by targeting CD47. Circ. Res. 100, 712-720. doi: 10.1161/01.RES.0000259579.35787.4e
75. Isenberg, J. S., Romeo, M. J., Maxhimer, J. B., Smedley, J., Frazier, W. A., and Roberts, D. D. (2008d). Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease. Ann. Surg. 247, 860-868. doi: 10.1097/SLA.0b013e31816c4006
76. Isenberg, J. S., Romeo, M. J., Yu, C., Yu, C. K., Nghiem, K., Monsale, J., et al. (2008e). Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 111, 613-623. doi: 10.1182/blood-2007-06-098392
77. Isenberg, J. S., Shiva, S., and Gladwin, M. (2009d). Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 21, 52-62. doi: 10.1016/j.niox.2009.05.005
78. Isenberg, J. S., Wink, D. A., and Roberts, D. D. (2006b). Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc. Res. 71, 785-793. doi: 10.1016/j.cardiores.2006.05.024
79. Isenberg, J. S., Yu, C., and Roberts, D. D. (2008f). Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem. Pharmacol. 75, 875-882. doi: 10.1016/j.bcp.2007.10.025
80. James, L. R., Griffiths, C. H., Garthwaite, J., and Bellamy, T. C. (2009). Inhibition of nitric oxide-activated guanylyl cyclase by calmodulin antagonists. Br. J. Pharmacol. 158, 1454-1464. doi: 10.1111/j.1476-5381.2009.00416.x
81. Jimenez, B., Volpert, O. V., Reiher, F., Chang, L., Munoz, A., Karin, M., et al. (2001). c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene 20, 3443-3448. doi: 10.1038/sj.onc.1204464
82. Kaur, S., Martin-Manso, G., Pendrak, M. L., Garfield, S. H., Isenberg, J. S., and Roberts, D. D. (2010). Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J. Biol. Chem. 285, 38923-38932. doi: 10.1074/jbc.M110.172304
83. Kaur, S., Soto-Pantoja, D. R., Stein, E. V., Liu, C., Elkahloun, A. G., Pendrak, M. L., et al. (2013). Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors. Sci. Rep. 3:1673. doi: 10.1038/srep01673
84. Kazerounian, S., Pitari, G. M., Ruiz-Stewart, I., Schulz, S., and Waldman, S. A. (2002). Nitric oxide activation of soluble guanylyl cyclase reveals high and low affinity sites that mediate allosteric inhibition by calcium. Biochemistry 41, 3396-3404. doi: 10.1021/bi0110894
85. Kelm, M., and Schrader, J. (1990). Control of coronary vascular tone by nitric oxide. Circ. Res. 66, 1561-1575. doi: 10.1161/01.RES.66.6.1561
86. Kharitonov, V. G., Sharma, V. S., Magde, D., and Koesling, D. (1997). Kinetics of nitric oxide dissociation from five- and six-coordinate nitrosyl hemes and heme proteins, including soluble guanylate cyclase. Biochemistry 36, 6814-6818. doi: 10.1021/bi970201o
87. Kondo, K., Bhushan, S., King, A. L., Prabhu, S. D., Hamid, T., Koenig, S., et al. (2013). H(2)S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation 127, 1116-1127. doi: 10.1161/CIRCULATIONAHA.112.000855
88. Kopp, H. G., Hooper, A. T., Broekman, M. J., Avecilla, S. T., Petit, I., Luo, M., et al. (2006). Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J. Clin. Invest. 116, 3277-3291. doi: 10.1172/JCI29314
89. Kram, L., Grambow, E., Mueller-Graf, F., Sorg, H., and Vollmar, B. (2013). The anti-thrombotic effect of hydrogen sulfide is partly mediated by an upregulation of nitric oxide synthases. Thromb. Res. 132, e112-117. doi: 10.1016/j.thromres.2013.07.010
90. Kumar, V., Martin, F., Hahn, M. G., Schaefer, M., Stamler, J. S., Stasch, J. P., et al. (2013). Insights into BAY 60-2770 activation and s-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes. Biochemistry 52, 3601-3608. doi: 10.1021/bi301657w
91. Lawler, J. W., Slayter, H. S., and Coligan, J. E. (1978). Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J. Biol. Chem. 253, 8609-8616.
92. Lawler, P. R., and Lawler, J. (2012). Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb. Perspect. Med. 2:a006627. doi: 10.1101/cshperspect.a006627
93. Lincoln, T. M., and Cornwell, T. L. (1993). Intracellular cyclic GMP receptor proteins. FASEB J. 7, 328-338.
94. Linder, A. E., McCluskey, L. P., Cole, K. R. 3rd. Lanning, K. M., and Webb, R. C. (2005). Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J. Pharmacol. Exp. Ther. 314, 9-15. doi: 10.1124/jpet.105.083634
95. Loscalzo, J. (2001). Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 88, 756-762. doi: 10.1161/hh0801.089861
96. Louis, J. C., Revel, M. O., and Zwiller, J. (1993). Activation of soluble guanylate cyclase through phosphorylation by protein kinase C in intact PC12 cells. Biochim. Biophys. Acta 1177, 299-306. doi: 10.1016/0167-4889(93)90126-A
97. Lucas, K. A., Pitari, G. M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., et al. (2000). Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52, 375-414.
98. Lundberg, J. O., Weitzberg, E., and Gladwin, M. T. (2008). The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov. 7, 156-167. doi: 10.1038/nrd2466
99. Ma, X., Beuve, A., and van den Akker, F. (2010). Crystal structure of the signaling helix coiled-coil domain of the beta1 subunit of the soluble guanylyl cyclase. BMC Struct. Biol. 10:2. doi: 10.1186/1472-6807-10-2
100. Ma, X., Sayed, N., Baskaran, P., Beuve, A., and van den Akker, F. (2008). PAS-mediated dimerization of soluble guanylyl cyclase revealed by signal transduction histidine kinase domain crystal structure. J. Biol. Chem. 283, 1167-1178. doi: 10.1074/jbc.M706218200
101. Ma, X., Sayed, N., Beuve, A., and van den Akker, F. (2007). NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanism. EMBO J. 26, 578-588. doi: 10.1038/sj.emboj.7601521
102. MacLauchlan, S., Yu, J., Parrish, M., Asoulin, T. A., Schleicher, M., Krady, M. M., et al. (2011). Endothelial nitric oxide synthase controls the expression of the angiogenesis inhibitor thrombospondin 2. Proc. Natl. Acad. Sci. U.S.A. 108, E1137-E1145. doi: 10.1073/pnas.1104357108
103. Majack, R. A., Cook, S. C., and Bornstein, P. (1986). Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. Proc. Natl. Acad. Sci. U.S.A. 83, 9050-9054. doi: 10.1073/pnas.83.23.9050
104. Margulis, A., and Sitaramayya, A. (2000). Rate of deactivation of nitric oxide-stimulated soluble guanylate cyclase: influence of nitric oxide scavengers and calcium. Biochemistry 39, 1034-1039. doi: 10.1021/bi992040p
105. Martin, F., Baskaran, P., Ma, X., Dunten, P. W., Schaefer, M., Stasch, J. P., et al. (2010). Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J. Biol. Chem. 285, 22651-22657. doi: 10.1074/jbc.M110.111559
106. Mateo, V., Brown, E. J., Biron, G., Rubio, M., Fischer, A., Deist, F. L., et al. (2002). Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization. Blood 100, 2882-2890. doi: 10.1182/blood-2001-12-0217
107. Maxhimer, J. B., Shih, H. B., Isenberg, J. S., Miller, T. W., and Roberts, D. D. (2009). Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective. Plast. Reconstr. Surg. 124, 1880-1889. doi: 10.1097/PRS.0b013e3181bceec3
108. Mayer, B., Kleschyov, A. L., Stessel, H., Russwurm, M., Munzel, T., Koesling, D., et al. (2009). Inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation. Mol. Pharmacol. 75, 886-891. doi: 10.1124/mol.108.052142
109. McDonald, J. F., Dimitry, J. M., and Frazier, W. A. (2003). An amyloid-like C-terminal domain of thrombospondin-1 displays CD47 agonist activity requiring both VVM motifs. Biochemistry 42, 10001-10011. doi: 10.1021/bi0341408
110. Mendes-Silverio, C. B., Leiria, L. O., Morganti, R. P., Anhe, G. F., Marcondes, S., Monica, F. Z., et al. (2012). Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway. PLoS ONE 7:e47223. doi: 10.1371/journal.pone.0047223
111. Meng, J., Ganesan Adaikan, P., and Srilatha, B. (2013). Hydrogen sulfide promotes nitric oxide production in corpus cavernosum by enhancing expression of endothelial nitric oxide synthase. Int. J. Impot. Res. 25, 86-90. doi: 10.1038/ijir.2012.39
112. Mergia, E., Russwurm, M., Zoidl, G., and Koesling, D. (2003). Major occurrence of the new alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain. Cell. Signal. 15, 189-195. doi: 10.1016/S0898-6568(02)00078-5
113. Meurer, S., Pioch, S., Gross, S., and Muller-Esterl, W. (2005). Reactive oxygen species induce tyrosine phosphorylation of and Src kinase recruitment to NO-sensitive guanylyl cyclase. J. Biol. Chem. 280, 33149-33156. doi: 10.1074/jbc.M507565200
114. Meurer, S., Pioch, S., Wagner, K., Muller-Esterl, W., and Gross, S. (2004). AGAP1, a novel binding partner of nitric oxide-sensitive guanylyl cyclase. J. Biol. Chem. 279, 49346-49354. doi: 10.1074/jbc.M410565200
115. Miller, T. W., Isenberg, J. S., and Roberts, D. D. (2009). Molecular regulation of tumor angiogenesis and perfusion via redox signaling. Chem. Rev. 109, 3099-3124. doi: 10.1021/cr8005125
116. Miller, T. W., Isenberg, J. S., and Roberts, D. D. (2010a). Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br. J. Pharmacol. 159, 1542-1547. doi: 10.1111/j.1476-5381.2009.00631.x
117. Miller, T. W., Isenberg, J. S., Shih, H. B., Wang, Y., and Roberts, D. D. (2010b). Amyloid-beta inhibits No-cGMP signaling in a CD36- and CD47-dependent manner. PLoS ONE 5:e15686. doi: 10.1371/journal.pone.0015686
118. Miller, T. W., Kaur, S., Ivins-O'Keefe, K., and Roberts, D. D. (2013). Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol. 32, 316-324. doi: 10.1016/j.matbio.2013.02.009
119. Miller, T. W., Wang, E. A., Gould, S., Stein, E. V., Kaur, S., Lim, L., et al. (2012). Hydrogen sulfide is an endogenous potentiator of T cell activation. J. Biol. Chem. 287, 4211-4221. doi: 10.1074/jbc.M111.307819
120. Mingone, C. J., Gupte, S. A., Ali, N., Oeckler, R. A., and Wolin, M. S. (2006). Thiol oxidation inhibits nitric oxide-mediated pulmonary artery relaxation and guanylate cyclase stimulation. Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L549-557. doi: 10.1152/ajplung.00331.2005
121. Mitrovic, V., Jovanovic, A., and Lehinant, S. (2011). Soluble guanylate cyclase modulators in heart failure. Curr. Heart Fail. Rep. 8, 38-44. doi: 10.1007/s11897-010-0045-1
122. Mittendorf, J., Weigand, S., Alonso-Alija, C., Bischoff, E., Feurer, A., Gerisch, M., et al. (2009). Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4, 853-865. doi: 10.1002/cmdc.200900014
123. Moncada, S., and Higgs, A. (1993). The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329, 2002-2012. doi: 10.1056/NEJM199312303292706
124. Mosher, D. F., and Adams, J. C. (2012). Adhesion-modulating/matricellular ECM protein families: a structural, functional and evolutionary appraisal. Matrix Biol. 31, 155-161. doi: 10.1016/j.matbio.2012.01.003
125. Moustafa, A., and Habara, Y. (2014). Hydrogen sulfide regulates Ca(2+) homeostasis mediated by concomitantly produced nitric oxide via a novel synergistic pathway in exocrine pancreas. Antioxid. Redox Signal. 20, 747-758. doi: 10.1089/ars.2012.5108
126. Mulsch, A., Busse, R., and Bassenge, E. (1988). Desensitization of guanylate cyclase in nitrate tolerance does not impair endothelium-dependent responses. Eur. J. Pharmacol. 158, 191-198. doi: 10.1016/0014-2999(88)90066-0
127. Munzel, T., Daiber, A., and Mulsch, A. (2005). Explaining the phenomenon of nitrate tolerance. Circ. Res. 97, 618-628. doi: 10.1161/01.RES.0000184694.03262.6d
128. Munzel, T., Feil, R., Mulsch, A., Lohmann, S. M., Hofmann, F., and Walter, U. (2003). Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase [corrected]. Circulation 108, 2172-2183. doi: 10.1161/01.CIR.0000094403.78467.C3
129. Murad, F., Mittal, C. K., Arnold, W. P., Katsuki, S., and Kimura, H. (1978). Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv. Cyclic Nucleotide Res. 9, 145-158.
130. Murad, F., Rapoport, R. M., and Fiscus, R. (1985). Role of cyclic-GMP in relaxations of vascular smooth muscle. J. Cardiovasc. Pharmacol. 7(Suppl. 3), S111-S118. doi: 10.1097/00005344-198500073-00013
131. Murthy, K. S. (2004). Modulation of soluble guanylate cyclase activity by phosphorylation. Neurochem. Int. 45, 845-851. doi: 10.1016/j.neuint.2004.03.014
132. Murthy, K. S. (2008). Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 receptors via Gbetagamma-dependent activation of c-Src kinase. J. Pharmacol. Exp. Ther. 325, 183-189. doi: 10.1124/jpet.107.132928
133. Mwaikambo, B. R., Sennlaub, F., Ong, H., Chemtob, S., and Hardy, P. (2006). Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 47, 4356-4364. doi: 10.1167/iovs.05-1656
134. Narizhneva, N. V., Byers-Ward, V. J., Quinn, M. J., Zidar, F. J., Plow, E. F., Topol, E. J., et al. (2004). Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction. J. Biol. Chem. 279, 21651-21657. doi: 10.1074/jbc.M311090200
135. Nioche, P., Berka, V., Vipond, J., Minton, N., Tsai, A. L., and Raman, C. S. (2004). Femtomolar sensitivity of a NO sensor from Clostridium botulinum. Science 306, 1550-1553. doi: 10.1126/science.1103596
136. Novelli, E. M., Kato, G. J., Ragni, M. V., Zhang, Y., Hildesheim, M. E., Nouraie, M., et al. (2012). Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Am. J. Hematol. 87, 326-330. doi: 10.1002/ajh.22274
137. Oldenborg, P. A., Zheleznyak, A., Fang, Y. F., Lagenaur, C. F., Gresham, H. D., and Lindberg, F. P. (2000). Role of CD47 as a marker of self on red blood cells. Science 288, 2051-2054. doi: 10.1126/science.288.5473.2051
138. Olea, C., Boon, E. M., Pellicena, P., Kuriyan, J., and Marletta, M. A. (2008). Probing the function of heme distortion in the H-NOX family. ACS Chem. Biol. 3, 703-710. doi: 10.1021/cb800185h
139. Olea, C. Jr. Herzik, M. A. Jr. Kuriyan, J., and Marletta, M. A. (2010). Structural insights into the molecular mechanism of H-NOX activation. Protein Sci. 19, 881-887. doi: 10.1002/pro.357
140. Pal, B., and Kitagawa, T. (2010). Binding of YC-1/BAY 41-2272 to soluble guanylate cyclase: A new perspective to the mechanism of activation. Biochem. Biophys. Res. Commun. 397, 375-379. doi: 10.1016/j.bbrc.2010.05.122
141. Parkinson, S. J., Jovanovic, A., Jovanovic, S., Wagner, F., Terzic, A., and Waldman, S. A. (1999). Regulation of nitric oxide-responsive recombinant soluble guanylyl cyclase by calcium. Biochemistry 38, 6441-6448. doi: 10.1021/bi990154v
142. Pellicena, P., Karow, D. S., Boon, E. M., Marletta, M. A., and Kuriyan, J. (2004). Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases. Proc. Natl. Acad. Sci. U.S.A. 101, 12854-12859. doi: 10.1073/pnas.0405188101
143. Piatakova, N. V., and Severina, I. S. (2012). [Soluble guanylate cyclase in the molecular mechanism underlying the therapeutic action of drugs]. Biomed. Khim. 58, 32-42. doi: 10.1134/S1990750812040075
144. Purohit, R., Fritz, B. G., The, J., Issaian, A., Weichsel, A., David, C. L., et al. (2014). YC-1 Binding to the beta subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the alpha subunit. Biochemistry 53, 101-114. doi: 10.1021/bi4015133
145. Purohit, R., Weichsel, A., and Montfort, W. R. (2013). Crystal structure of the Alpha subunit PAS domain from soluble guanylyl cyclase. Protein Sci. 22, 1439-1444. doi: 10.1002/pro.2331
146. Rabinovitch, M. (2007). Pathobiology of pulmonary hypertension. Annu. Rev. Pathol. 2, 369-399. doi: 10.1146/annurev.pathol.2.010506.092033
147. Ramanathan, S., Mazzalupo, S., Boitano, S., and Montfort, W. R. (2011). Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration. Biochemistry 50, 7787-7799. doi: 10.1021/bi201060c
148. Rauch, A., Leipelt, M., Russwurm, M., and Steegborn, C. (2008). Crystal structure of the guanylyl cyclase Cya2. Proc. Natl. Acad. Sci. U.S.A. 105, 15720-15725. doi: 10.1073/pnas.0808473105
149. Rindone, J. P., and Sloane, E. P. (1992). Cyanide toxicity from sodium nitroprusside: risks and management. Ann. Pharmacother. 26, 515-519.
150. Rogers, N. M., Roberts, D. D., and Isenberg, J. S. (2013). Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow. Ann. Surg. 258, 184-191. doi: 10.1097/SLA.0b013e31827e52e1
151. Rogers, N. M., Thomson, A. W., and Isenberg, J. S. (2012). Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 23, 1538-1550. doi: 10.1681/ASN.2012020137
152. Ruiz-Stewart, I., Tiyyagura, S. R., Lin, J. E., Kazerounian, S., Pitari, G. M., Schulz, S., et al. (2004). Guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism. Proc. Natl. Acad. Sci. U.S.A. 101, 37-42. doi: 10.1073/pnas.0305080101
153. Russwurm, M., and Koesling, D. (2004). NO activation of guanylyl cyclase. EMBO J. 23, 4443-4450. doi: 10.1038/sj.emboj.7600422
154. Russwurm, M., Mergia, E., Mullershausen, F., and Koesling, D. (2002). Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J. Biol. Chem. 277, 24883-24888. doi: 10.1074/jbc.M110570200
155. Russwurm, M., Wittau, N., and Koesling, D. (2001). Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes. J. Biol. Chem. 276, 44647-44652. doi: 10.1074/jbc.M105587200
156. Sayed, N., Baskaran, P., Ma, X., van den Akker, F., and Beuve, A. (2007). Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc. Natl. Acad. Sci. U.S.A. 104, 12312-12317. doi: 10.1073/pnas.0703944104
157. Sayed, N., Kim, D. D., Fioramonti, X., Iwahashi, T., Duran, W. N., and Beuve, A. (2008). Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ. Res. 103, 606-614. doi: 10.1161/CIRCRESAHA.108.175133
158. Scheef, E. A., Sorenson, C. M., and Sheibani, N. (2009). Attenuation of proliferation and migration of retinal pericytes in the absence of thrombospondin-1. Am. J. Physiol. Cell Physiol. 296, C724-C734. doi: 10.1152/ajpcell.00409.2008
159. Schermuly, R. T., Janssen, W., Weissmann, N., Stasch, J. P., Grimminger, F., and Ghofrani, H. A. (2011). Riociguat for the treatment of pulmonary hypertension. Expert Opin. Investig. Drugs 20, 567-576. doi: 10.1517/13543784.2011.565048
160. Schrammel, A., Behrends, S., Schmidt, K., Koesling, D., and Mayer, B. (1996). Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol. Pharmacol. 50,1-5.
161. Schroder, H., Leitman, D. C., Bennett, B. M., Waldman, S. A., and Murad, F. (1988). Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. J. Pharmacol. Exp. Ther. 245, 413-418.
162. Schwartz, M. A., Brown, E. J., and Fazeli, B. (1993). A 50-kDa integrin-associated protein is required for integrin-regulated calcium entry in endothelial cells. J. Biol. Chem. 268, 19931-19934.
163. Seeger, F., Quintyn, R., Tanimoto, A., Williams, G. J., Tainer, J. A., Wysocki, V. W., et al. (2014). Interfacial Residues promote an optimal alignment of the catalytic center in human soluble guanylate cyclase: heterodimerization is required but not sufficient for activity. Biochemistry. doi: 10.102/bi500129k. [Epub ahead print].
164. Serfass, L., Carr, H. S., Aschenbrenner, L. M., and Burstyn, J. N. (2001). Calcium ion downregulates soluble guanylyl cyclase activity: evidence for a two-metal ion catalytic mechanism. Arch. Biochem. Biophys. 387, 47-56. doi: 10.1006/abbi.2000.2090
165. Sick, E., Niederhoffer, N., Takeda, K., Landry, Y., and Gies, J. P. (2009). Activation of CD47 receptors causes histamine secretion from mast cells. Cell. Mol. Life Sci. 66, 1271-1282. doi: 10.1007/s00018-009-8778-2
166. Smadja, D. M., d'Audigier, C., Bieche, I., Evrard, S., Mauge, L., Dias, J. V., et al. (2011). Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler. Thromb. Vasc. Biol. 31, 551-559. doi: 10.1161/ATVBAHA.110.220624
167. Stasch, J. P., and Evgenov, O. V. (2013). Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb. Exp. Pharmacol. 218, 279-313. doi: 10.1007/978-3-642-38664-0_12
168. Stasch, J. P., Pacher, P., and Evgenov, O. V. (2011). Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123, 2263-2273. doi: 10.1161/CIRCULATIONAHA.110.981738
169. Stasch, J. P., Schmidt, P. M., Nedvetsky, P. I., Nedvetskaya, T. Y. H. S. A., Meurer, S., et al. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 116, 2552-2561. doi: 10.1172/JCI28371
170. Stenina, O. I., Ustinov, V., Krukovets, I., Marinic, T., Topol, E. J., and Plow, E. F. (2005). Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites. FASEB J. 19, 1893-1895.
171. Stone, J. R., and Marletta, M. A. (1996). Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide. Biochemistry 35, 1093-1099. doi: 10.1021/bi9519718
172. Stone, J. R., Sands, R. H., Dunham, W. R., and Marletta, M. A. (1995). Electron paramagnetic resonance spectral evidence for the formation of a pentacoordinate nitrosyl-heme complex on soluble guanylate cyclase. Biochem. Biophys. Res. Commun. 207, 572-577. doi: 10.1006/bbrc.1995.1226
173. Taraboletti, G., Roberts, D., Liotta, L. A., and Giavazzi, R. (1990). Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J. Cell Biol. 111, 765-772. doi: 10.1083/jcb.111.2.765
174. Thomas, D. D., Ridnour, L. A., Espey, M. G., Donzelli, S., Ambs, S., Hussain, S. P., et al. (2006). Superoxide fluxes limit nitric oxide-induced signaling. J. Biol. Chem. 281, 25984-25993. doi: 10.1074/jbc.M602242200
175. Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P. J., and Bouck, N. (1993). Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 122, 497-511. doi: 10.1083/jcb.122.2.497
176. Tsai, A. L., Berka, V., Sharina, I., and Martin, E. (2011). Dynamic ligand exchange in soluble guanylyl cyclase (sGC): implications for sGC regulation and desensitization. J. Biol. Chem. 286, 43182-43192. doi: 10.1074/jbc.M111.290304
177. Tsai, A. L., Martin, E., Berka, V., and Olson, J. S. (2012a). How do heme-protein sensors exclude oxygen? Lessons learned from cytochrome c', Nostoc puntiforme heme nitric oxide/oxygen-binding domain, and soluble guanylyl cyclase. Antioxid. Redox Signal. 17, 1246-1263. doi: 10.1089/ars.2012.4564
178. Tsai, E. J., Liu, Y., Koitabashi, N., Bedja, D., Danner, T., Jasmin, J. F., et al. (2012b). Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ. Res. 110, 295-303. doi: 10.1161/CIRCRESAHA.111.259242
179. Tsao, P. W., and Mousa, S. A. (1995). Thrombospondin mediates calcium mobilization in fibroblasts via its Arg-Gly-Asp and carboxyl-terminal domains. J. Biol. Chem. 270, 23747-23753. doi: 10.1074/jbc.270.40.23747
180. Underbakke, E. S., Iavarone, A. T., and Marletta, M. A. (2013). Higher-order interactions bridge the nitric oxide receptor and catalytic domains of soluble guanylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 110, 6777-6782. doi: 10.1073/pnas.1301934110
181. Venema, R. C., Venema, V. J., Ju, H., Harris, M. B., Snead, C., Jilling, T., et al. (2003). Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am. J. Physiol. Heart Circ. Physiol. 285, H669-H678. doi: 10.1152/ajpheart.01025.2002
182. Vernon-Wilson, E. F., Kee, W. J., Willis, A. C., Barclay, A. N., Simmons, D. L., and Brown, M. H. (2000). CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1. Eur. J. Immunol. 30, 2130-2137. doi: 10.1002/1521-4141(2000)30:8%3C2130::AID-IMMU2130%3E3.0.CO;2-8
183. Voetsch, B., Jin, R. C., and Loscalzo, J. (2004). Nitric oxide insufficiency and atherothrombosis. Histochem. Cell Biol. 122, 353-367. doi: 10.1007/s00418-004-0675-z
184. Vogel, T., Guo, N. H., Krutzsch, H. C., Blake, D. A., Hartman, J., Mendelovitz, S., et al. (1993). Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J. Cell. Biochem. 53, 74-84. doi: 10.1002/jcb.240530109
185. Wang, X. Q., and Frazier, W. A. (1998). The thrombospondin receptor CD47 (IAP) modulates and associates with alpha2 beta1 integrin in vascular smooth muscle cells. Mol. Biol. Cell 9, 865-874. doi: 10.1091/mbc.9.4.865
186. Wedel, B., Humbert, P., Harteneck, C., Foerster, J., Malkewitz, J., Bohme, E., et al. (1994). Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U.S.A. 91, 2592-2596. doi: 10.1073/pnas.91.7.2592
187. Weinert, E. E., Phillips-Piro, C. M., Tran, R., Mathies, R. A., and Marletta, M. A. (2011). Controlling conformational flexibility of an O(2)-binding H-NOX domain. Biochemistry 50, 6832-6840. doi: 10.1021/bi200788x
188. Weinert, E. E., Plate, L., Whited, C. A., Olea, C., and Marletta, M. A. Jr. (2010). Determinants of ligand affinity and heme reactivity in H-NOX domains. Angew. Chem. Int. Ed. Engl. 49, 720-723. doi: 10.1002/anie.200904799
189. Weitzberg, E., and Lundberg, J. O. (2013). Novel aspects of dietary nitrate and human health. Annu. Rev. Nutr. 33, 129-159. doi: 10.1146/annurev-nutr-071812-161159
190. Whiteman, M., and Moore, P. K. (2009). Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? J. Cell. Mol. Med. 13, 488-507. doi: 10.1111/j.1582-4934.2009.00645.x
191. Wilkinson, B., Koenigsknecht-Talboo, J., Grommes, C., Lee, C. Y., and Landreth, G. (2006). Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J. Biol. Chem. 281, 20842-20850. doi: 10.1074/jbc.M600627200
192. Winger, J. A., Derbyshire, E. R., Lamers, M. H., Marletta, M. A., and Kuriyan, J. (2008). The crystal structure of the catalytic domain of a eukaryotic guanylate cyclase. BMC Struct. Biol. 8:42. doi: 10.1186/1472-6807-8-42
193. Winger, J. A., and Marletta, M. A. (2005). Expression and characterization of the catalytic domains of soluble guanylate cyclase: interaction with the heme domain. Biochemistry 44, 4083-4090. doi: 10.1021/bi047601d
194. Winter, M. B., Herzik, M. A. Jr. Kuriyan, J., and Marletta, M. A. (2011). Tunnels modulate ligand flux in a heme nitric oxide/oxygen binding (H-NOX) domain. Proc. Natl. Acad. Sci. U.S.A. 108, E881-E889. doi: 10.1073/pnas.1114038108
195. Wu, S., Moore, T. M., Brough, G. H., Whitt, S. R., Chinkers, M., Li, M., et al. (2000). Cyclic nucleotide-gated channels mediate membrane depolarization following activation of store-operated calcium entry in endothelial cells. J. Biol. Chem. 275, 18887-18896. doi: 10.1074/jbc.M002795200
196. Wu, X. B., Brune, B., von Appen, F., and Ullrich, V. (1992). Reversible activation of soluble guanylate cyclase by oxidizing agents. Arch. Biochem. Biophys. 294, 75-82. doi: 10.1016/0003-9861(92)90139-N
197. Wykes, V., and Garthwaite, J. (2004). Membrane-association and the sensitivity of guanylyl cyclase-coupled receptors to nitric oxide. Br. J. Pharmacol. 141, 1087-1090. doi: 10.1038/sj.bjp.0705745
198. Xi, G., Shen, X. C., Wai, C., and Clemmons, D. R. (2013). Recruitment of Nox4 to a plasma membrane scaffold is required for localized reactive oxygen species generation and sustained Src activation in response to insulin-like growth factor-I. J. Biol. Chem. 288, 15641-15653. doi: 10.1074/jbc.M113.456046
199. Yao, M., Roberts, D. D., and Isenberg, J. S. (2011). Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacol. Res. 63, 13-22. doi: 10.1016/j.phrs.2010.10.014
200. Yao, M., Rogers, N. M., Csanyi, G., Rodriguez, A. I., Ross, M. A., St.Croix, C., et al. (2014). Thrombospondin-1 activation of signal-regulatory protein-alpha stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury. J. Am. Soc. Nephrol. doi: 10.1681/ASN.2013040433. [Epub ahead of print].
201. Zabel, U., Hausler, C., Weeger, M., and Schmidt, H. H. (1999). Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione s-transferase affinity tag. J. Biol. Chem. 274, 18149-18152. doi: 10.1074/jbc.274.26.18149
202. Zabel, U., Kleinschnitz, C., Oh, P., Nedvetsky, P., Smolenski, A., Muller, H., et al. (2002). Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nat. Cell Biol. 4, 307-311. doi: 10.1038/ncb775
203. Zhao, Y., Brandish, P. E., Ballou, D. P., and Marletta, M. A. (1999). A molecular basis for nitric oxide sensing by soluble guanylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 96, 14753-14758. doi: 10.1073/pnas.96.26.14753
204. Zhao, Y., Brandish, P. E., Di Valentin, M., Schelvis, J. P., Babcock, G. T., and Marletta, M. A. (2000). Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39, 10848-10854. doi: 10.1021/bi9929296
205. Zhou, Z., Sayed, N., Pyriochou, A., Roussos, C., Fulton, D., Beuve, A., et al. (2008). Protein kinase G phosphorylates soluble guanylyl cyclase on serine 64 and inhibits its activity. Arterioscler. Thromb. Vasc. Biol. 28, 1803-1810. doi: 10.1161/ATVBAHA.108.165043
206. Zwiller, J., Revel, M. O., and Basset, P. (1981). Evidence for phosphorylation of rat brain guanylate cyclase by cyclic AMP-dependent protein kinase. Biochem. Biophys. Res. Commun. 101, 1381-1387. doi: 10.1016/0006-291X(81)91600-4